Showing 1 - 8 of 8 Cirrhosis

Status: Enrolling

Investigator: Dipan Shah

Study Coordinator: Bevin Lopez

Phone: 346.238.5810

This study is designed to evaluate the efficacy of Dotarem enhanced MRI compared to Magnevist and Gadavist enhanced MRI in identifying myocardial infarct. Eighty patients will be recruited for this study. Patients with known CAD and undergoing c ... Read more >

Status: Enrolling

Investigator: Ahmed Gaber

Study Coordinator: Marcos De Oliveira

Phone: 171.344.19837

This is a randomized, double-blind, placebo-controlled trial in de novo kidney transplant patients to determine if the addition of fingolimod (brand name Gilenya®, candidate name- FTY720) on the background of standard immunosuppression will prev ... Read more >

Status: Open Not Enrolling

Investigator: Maen Abdelrahim

Study Coordinator: Safiya Joseph

Phone: 203.308.8567

The purpose of this study is to evaluate the efficacy and safety of NIS793 in combination with gemcitabine/nab-paclitaxel versus gemcitabine/nab-paclitaxel and placebo in first-line metastatic pancreatic ductal adenocarcinoma (mPDAC). This st ... Read more >

Status: Enrolling

Investigator: David Victor

Study Coordinator:

Phone:

This Phase 3 study is conducted to evaluate lanifibranor in adults with NASH and liver fibrosis stage 2 or 3. NASH - Nonalcoholic Steatohepatitis - Drug: IVA337 vs Drug: Placebo This Phase 3 study is conducted to evaluate lanifibranor in adu ... Read more >

Status: Open Not Enrolling

Investigator: David Victor

Study Coordinator: Nicole Hinton

Phone: 281.755.0796

The purpose of this randomized study is to assess safety and effectiveness of BMS-986263 in adults with compensated cirrhosis (chronic liver disease) from nonalcoholic steatohepatitis (fatty liver disease) (NASH). ... Read more >

Status: Open Not Enrolling

Investigator: Sherif Nagueh

Study Coordinator: Nirali Patel

Phone: 713.441.2116

Hypertrophic cardiomyopathy (HCM) is the most common monogenic heart disease and the most frequent cause of sudden cardiac death (SCD) in the young. It is characterized by unexplained left ventricular hypertrophy (LVH), diffuse and patchy fibros ... Read more >

Status: Enrolling

Investigator: Zeenat Safdar

Study Coordinator: Jennifer Lee

Phone: 713.363.7537

This registry will collect data on the strategies used to achieve a diagnosis of Idiopathic Pulmonary Fibrosis (IPF) and Chronic Fibrosing Interstitial Lung Disease with Progressive Phenotype (ILD) and the treatment and management efforts applie ... Read more >

Status: Enrolling

Investigator: David Victor

Study Coordinator: Lindsay Barter

Phone: 502.417.6664

The goals of this clinical study are to learn more about the study drugs, semaglutide (SEMA) with the fixed-dose combination (FDC) of cilofexor/firsocostat (CILO/FIR), and understand whether they cause fibrosis improvement and Nonalcoholic Steat ... Read more >